Co-Founder & CEO of Reistone Biopharma
Dr. Min Wang Irwin is the CEO of Reistone Biopharma which is incorporated in Shanghai Zhangjiang in January 2018. Most recently, Dr. Irwin worked in Qiming Venture Partners as venture partner. Dr. Irwin has brought more than 20 years’ experience in RD, partnering, market access and organization development in global and China. She has established several big medical and development teams including product development, medical affairs, regulatory affairs, project management as well worked closely with company commercial teams for product lunch and life cycle management. In addition, she worked extensively with BD to complete several product licensing deals. Under her leadership, teams had successfully received NDA approval for close to 20 drugs in small molecules, biological products, medical devices and consumer healthcare products across many therapeutic areas in China and Canada. Dr. Irwin worked at Takeda as VP, site head of Takeda Development Center Asia. She also worked in GlaxoSmithKline’s R&D Center in Shanghai where she served as Vice President China Medicine Development since January 2013. Prior to joining GSK, she was with Bayer Healthcare for 13 years in China and Canada. Dr. Irwin’s career also includes Clinical Science and Research with Parke-Davis and biotech startup company, Dimethaid Pharmaceutical. Dr. Irwin has a Ph.D. in Diabetes Research from University of Toronto, a Master of Science degree in Anti-Infection after Burn Injury and a Doctor of Medicine, both from Third PLA Medical University in China.